血府逐瘀方治疗冠心病心绞痛随机对照试验的Meta分析

Xuefu Zhuyu prescription for the treatment of angina pectoris: a Meta-analysis of randomized controlled trials

关键词:  血府逐瘀方  冠心病心绞痛  Meta分析  随机对照试验

Key words:  Xuefu Zhuyu prescription  coronary heart disease angina pectoris  Meta-analysis  randomized controlled trial

摘要:

[目的] 对血府逐瘀方治疗冠心病心绞痛的有效性及安全性进行定量分析,以期为其临床应用提供理论依据,并在一定程度上指导辨证。[方法] 检索Web of science, Pubmed, Cochrane library,Elsevier,中国知网,万方数据知识服务平台,维普期刊资源整合服务平台及中国生物医学文献数据库(CBM)截至2015年12月已经发表的中英文文献,纳入单独使用血府逐瘀方或者合并西医常规用药,与西医常规用药治疗冠心病心绞痛进行疗效评价的临床随机对照试验。所有符合纳入标准的文章,将用Revman 5.3软件进行统计分析,结局的效应指标以相对危险度(RR)及95%可信区间(CI)来表示。[结果] 共有10篇文献745例冠心病心绞痛患者符合纳入标准,合并效应检验结果显示治疗组疗效好于对照组,P<0.000 01,RR=1.27,95%CI=[1.19, 1.37],且尚未见有关血府逐瘀方的严重不良反应报道。[结论] 血府逐瘀方在冠心病心绞痛的治疗方面,具有疗效显著且不良反应少的特点,但由于纳入研究的样本质量较低,可能存在发表偏倚等因素影响,需要更加严谨的大样本多中心随机对照试验对血府逐瘀方的有效性及安全性进行验证。

Abstract:

[Objective] To quantitative evaluate the clinical effects of coronary heart disease with angina pectoris by Xuefu Zhuyu prescription. [Methods] Retrieving total 8 databases, such as Cochrane Library, Pubmed, Web of Science, Elsevier, CNKI, Wanfang, CBM, and VIP, the literatures as of December 2015 were published in both English and Chinese, which were absorbed into angina pectoris clinical randomized controlled trials that the treatment of Xuefu Zhuyu prescription alone or merged with conventional Western medicine, and compared with the treatment of conventional Western medicine. All reports which were selected in accordance with strict inclusion criteria would be analyzed with Revman 5.3 software for statistical analysis, end effect index to relative risk (RR) and 95% confidence interval (CI). [Results] A total of 10 articles were 745 cases of patients with angina pectoris included in the standard. The result showed that the treatment group effect was better than the control group (P<0.000 01; RR=1.27; 95%CI=[1.19, 1.37]). No serious adverse reactions of Xuefu Zhuyu prescription had been reported. [Conclusion] Application in the treatment of angina pectoris, Xuefu Zhuyu prescription could improve the efficiency, and had the characteristics of less adverse reaction. However, due to effect of the low quality of the absorbed studies of samples, publication bias and other factors, there has to be more high-quality, multiple-center, large-sample randomized controlled trials to validate the curative effect of Xuefu Zhuyu prescription.